Skip to main content

Table 1 Patient and disease characteristics

From: Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

Patient characteristics No-ATG ATG p value
Number of patients 421 145  
Recipient age at SCT (years, range) 43.7 (18–68) 48.8 (20–69) 0.002
Recipient gender, n (%) 0.24
 Male 215 (51.3%) 82 (56.9%)  
 Female 204 (48.7%) 62 (43.1%)
Year of SCT (median), year (%) 2011 (2006–2013) 2012 (2006–2013) <10−5
Interval from diagnosis to SCT (median days) 156 156 0.79
Median follow-up a (months, range) 16 (1.5–93) 21 (1–106) 0.81
Donor age (years, range) 41 (8–70) 47 (10–65) 0.003
Donor gender, n (%)  
 Male 236 (56.3%) 70 (48.6%) 0.11
 Female 183 (43.7%) 74 (51.4%)
Female donor to male recipient, n (%) 96 (23%) 44 (30.8%) 0.06
Diagnosis, n (%) 0.05
 De novo AML 391 (92.9%) 127 (87.6%)  
 Secondary AML 30 (7.1%) 18 (12.4%)
Cytogenetics in de novo AML, n (% of available data) 0.60
 Good 18 (16.2%) 6 (9%)  
 Intermediate 76 (68.5%) 50 (74.6%)
 Poor 17 (15.3%) 11 (16.4%)
 Not available/failed 280 60
Source of SC, n (%) <10−4
 BM 84 (20%) 10 (6.9%)  
 PB 337 (80%) 135 (93.1%)
In vivo T cell depletion, n (%)
 Thymoglobuline 0 138 (95.2%)  
 ATG Fresenius 4 (2.8%)
 Missing brand of ATG 3 (2%)
 Mean dose of thymoglobuline (mg/kg) (range) 5 (2.5–15.8)
 Thymo ≤ 6 mg/kg 98 (73.7%)
 Thymo > 6 mg/kg 35 (26.3%)
 Unknown dose of thymoglobuline 12
Post-transplant GVHD prophylaxis <10−4
 CsA 4 (1%) 42 (29%)  
 CsA + MTX 372 (88.4%) 57 (39.3%)
 CsA/FK 506 + MMF 35 (8.3%) 17 (11.7%)
 Other 10 (2.4%) 29 (20%)
Patient positive CMV serology, n (%) 362 (87%) 107 (74.3%) <10−4
Donor positive CMV serology, n (%) 330 (80.1%) 104 (72.7%) 0.07
CMV risk, n (%) 0.008
 Low 33 (8%) 22 (15.5%)  
 Intermediate 328 (77.9%) 103 (71%)
 High 49 (12%) 17 (12%)
  1. CMV risk low = negative recipient and donor serology, high positive recipient and negative donor serology, intermediate: all other combinations
  2. AML acute myeloid leukemia, ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, CsA cyclosporine A, MMF mycophenolate mofetil, MTX methotrexate, PB peripheral blood, SC stem cells, SCT stem cell transplantation
  3. aFor alive patients